Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

Help shape the future of lupus! Do you want to provide a game-changing contribution to lupus-centered research? Help us make clinical research more efficient and effective. If you have lupus, you can participate by providing samples we can study, such as blood, urine, saliva, and/or stool, to help doctors combat lupus head-on. Compensation provided.

Are you someone living with Parkinson's disease? If so, you are aware that in addition to symptoms affecting movement, people with Parkinson's disease also experience non-motor symptoms such as problems with mood and motivation which can be difficult to treat. If you have been living with Parkinson's disease for at least 5 years and take medication for Parkinson's disease, you may be eligible to participate in a research study aimed at treating low motivation with a form of non-invasive brain stimulation called transcranial magnetic stimulation (TMS).

Do you have a new diagnosis of Acute Myeloid Leukemia and are looking for another treatment option? In this study, we are looking to see if the study drug (Tagraxofusp) can help control Leukemia or achieve remission.

This study is designed to determine whether our voice-based recall system can recall your food from the past 24 hours in comparison to the ASA-24 web based method.

The purpose of this study is to learn if the Fitlight Vision Board can measure how fast you can respond to a series of lights.

The purpose of this research study is to explore common experiences related to forming stepfamily relationships (and it's completely okay if you do not identify as a "stepfamily").

The purpose of this study is to find out if we can improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by combining two drugs for acute lymphoblastic leukemia. In this study you will be given the first study drug (Inotuzumab Ozogamicin) for up to 7 weeks and then a second leukemia drug (Blinatumomab) for up to 31 weeks.

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment.